AstraZeneca to boost cell therapy operations with $300m manufacturing investment
Investment in the US manufacturing facility will accelerate AstraZeneca’s ambition to make next-generation cell therapy a reality, the company asserts.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
